1. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
Paul B Eckburg, Lori Muir, Ian A Critchley, Susannah Walpole, Hanna Kwak, Anne-Marie Phelan, Gary Moore, Akash Jain, Tim Keutzer, Aaron Dane, David Melnick, Angela K Talley Clinical TrialN Engl J Med. 2022 Apr 7;386(14):1327-1338.doi: 10.1056/NEJMoa2105462.
Background:There is a need for oral antibiotic agents that are effective against multidrug-resistant gram-negative uropathogens. Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales, including extended-spectrum beta-lactamase-producing and fluoroquinolone-resistant strains.
2. Peficitinib hydrobromide to treat rheumatoid arthritis
S R Gutiérrez-Ureña, E L Amaya-Cabrera, J F Uribe-Martínez, M E Ventura-Valenzuela, C Rosal-Arteaga, G E Martínez-Bonilla, V González-Díaz, O Almengor-Montenegro, S Cerpa-Cruz Drugs Today (Barc). 2020 Aug;56(8):505-514.doi: 10.1358/dot.2020.56.8.3123469.
Peficitinib hydrobromide is a small Janus kinase inhibitor (JAK1, JAK2, JAK3 and TYK2) molecule for the treatment of rheumatoid arthritis (RA). Phase II and phase III clinical trials and extension studies with different doses have been conducted to assess the drug's efficacy and safety with substantially improved outcomes observed in RA. This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX. The findings from studies of this new JAK inhibitor have shown that, both in monotherapy as well as in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), it has efficacy, safety and tolerability in RA patients.
3. Tebipenem pivoxil hydrobromide-No PICC, no problem!
Varun Sodhi, Kelli A Kronsberg, Mickayla Clark, Jonathan C Cho Pharmacotherapy. 2021 Sep;41(9):748-761.doi: 10.1002/phar.2614.Epub 2021 Aug 17.
Tebipenem pivoxil hydrobromide is a novel orally bioavailable prodrug of tebipenem, a carbapenem antimicrobial, that binds to penicillin-binding proteins, inhibiting the synthesis of the bacterial cell wall. This results in weakening of peptidoglycan, leading to lysis of bacterial cells. Tebipenem displays a broad spectrum of activity against anaerobic, gram-positive, and gram-negative pathogens, including extended-spectrum β-lactamase producing Enterobacterales. In a large phase 3 clinical trial (ADAPT-PO), oral tebipenem pivoxil hydrobromide 600 mg every 8 h was shown to be non-inferior to intravenous ertapenem 1 g every 24 h. Overall response at test of cure was 58.8% [264/449] in the tebipenem pivoxil hydrobromide group compared to 61.6% [258/419] in the ertapenem group for the treatment of complicated urinary tract infections, including acute pyelonephritis. At the test of cure, clinical cure rates were 93.1% and 93.6% and microbiological eradication was 59.5% and 63.5% with tebipenem pivoxil hydrobromide and ertapenem, respectively. The most common adverse reactions associated with tebipenem pivoxil hydrobromide are diarrhea, headache, and nausea. As with other carbapenems, tebipenem pivoxil hydrobromide is expected to have the potential to decrease the seizure threshold and will likely require renal dosage adjustment for patients with altered renal function due to high renal clearance. If approved in the United States, tebipenem pivoxil hydrobromide can serve as a potential oral antimicrobial option to decrease hospital length of stay and prevent hospital admissions due to resistant pathogens.
